Quick Answer
Pasithea Therapeutics Corp. reported Earnings Per Share Diluted of $2.91 (loss) per share for the year ending 2025.
- Pasithea Therapeutics Corp. showed an increase of +77.1% in Earnings Per Share Diluted from 2024 to 2025.
- This data is from Pasithea Therapeutics Corp.'s annual report (Form 10-K), filed with the SEC on March 30, 2026.
- XBRL data for this metric is available from 2021 to 2025 (4 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2021: $0.09 (loss) per share | Q3 2021: $0.17 (loss) per share | Q1 2022: $0.01 (loss) per share | Q2 2022: $0.02 (loss) per share | Q3 2022: $0.01 (loss) per share | Q1 2023: $0.01 (loss) per share | Q2 2023: $0.01 (loss) per share | Q3 2023: $0.00 per share | Q1 2024: $3.70 (loss) per share | Q2 2024: $3.71 (loss) per share | Q3 2024: $2.87 (loss) per share | Q1 2025: $1.61 (loss) per share | Q2 2025: $0.66 (loss) per share | Q3 2025: $0.41 (loss) per share.
- Over the full 4 years of available data (2021 to 2025), Pasithea Therapeutics Corp.'s Earnings Per Share Diluted has declined by 1,285.7%.
- Historical annual values: Fiscal year 2025: $2.91 (loss) per share | Fiscal year 2024: $12.69 (loss) per share | Fiscal year 2022: $0.53 (loss) per share | Fiscal year 2021: $0.21 (loss) per share.
- Data sourced from SEC EDGAR public filings as of August 10, 2026.
Last verified: